Systematic Financial Management LP Has $18.75 Million Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Systematic Financial Management LP raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 14.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,410,346 shares of the medical instruments supplier's stock after acquiring an additional 300,785 shares during the period. Systematic Financial Management LP owned 5.93% of AngioDynamics worth $18,752,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in ANGO. Segall Bryant & Hamill LLC grew its stake in shares of AngioDynamics by 142.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock valued at $7,091,000 after buying an additional 535,958 shares during the period. Millennium Management LLC grew its stake in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock valued at $10,850,000 after buying an additional 529,861 shares during the period. First Eagle Investment Management LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter valued at $1,321,000. Royce & Associates LP grew its stake in shares of AngioDynamics by 10.8% during the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after buying an additional 96,138 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of AngioDynamics by 110.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier's stock valued at $1,240,000 after buying an additional 83,622 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the company's stock in a transaction dated Monday, October 7th. The shares were bought at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This trade represents a 3.02 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have acquired a total of 22,568 shares of company stock worth $135,847 in the last 90 days. 5.40% of the stock is owned by insiders.

AngioDynamics Trading Down 0.6 %

NASDAQ:ANGO traded down $0.04 during trading hours on Thursday, reaching $7.10. 311,585 shares of the company's stock were exchanged, compared to its average volume of 517,415. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25. The business's 50-day simple moving average is $6.86 and its two-hundred day simple moving average is $6.84.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. The company's revenue was down 14.2% compared to the same quarter last year. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ANGO shares. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, October 4th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of AngioDynamics in a research report on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.